Combination treatment for low platelet counts in immune thrombocytopenia
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This study tests a new combination of two medicines to help raise platelet counts in people with persistent or chronic immune thrombocytopenia (ITP) whose platelets are still low after standard treatments. The goal is to see if this combination works better and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have had ITP for at least 3 months.
- Your platelet counts have been below 30 for at least a week before starting the study.
- Standard treatments like steroids or immunoglobulins did not work for you, or your ITP came back after treatment.
- You are not currently taking certain blood thinners or antiplatelet drugs like aspirin or clopidogrel.
- You have not had a heart attack, stroke, or blood clot in the past year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a modified starting dose of avatrombopag, a medication that helps raise platelet counts, in adults with immune thrombocytopenia (ITP) who have not responded well to first-line steroid treatments. The goal is to see if this new dosing is effective and safe.
This study tests a combination of multiple drugs given in sequence to adults with newly diagnosed immune thrombocytopenia (ITP), a condition of low platelets. The goal is to see if this approach improves platelet counts and is safe.
This study compares two treatments for people with ITP (low platelets) whose condition didn't improve after steroids. One group gets only eltrombopag (a platelet booster pill) and the other gets eltrombopag plus ripertamab (an experimental antibody). The goal is to see if the combination works better at raising platelet levels.
This study tests drugs called thrombopoietin agonists to help raise platelet levels in adults with ITP. It may help reduce bleeding risk and improve daily life.
This study tests whether adding another medicine (telitacicept) to a standard platelet-boosting drug (eltrombopag) works better than eltrombopag alone for adults with ITP that hasn't improved with steroids. The goal is to help raise your platelet counts and reduce bleeding risk.
This study compares two medicines for adults with newly diagnosed ITP (a low platelet count that can cause bleeding). One medicine is rituximab, which helps the immune system stop attacking platelets, and the other is avatrombopag, which helps the body make more platelets. You may join if your platelet count is very low and standard steroid treatment hasn't worked.
Hear when a new ITP - Immune Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.